ArticleBritish journal of clinical pharmacology2026
Trends in first-line monotherapy and combination therapy for hypertension in UK primary care.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in first-line monotherapy and combination therapy for hypertension in UK primary care.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDebate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first-line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first-line monotherapy for all patients. It is unknown if first-line combination therapy use is increasing despite this recommendation. This study aims to assess trends in prescriptions for first-line antihypertensive monotherapy and combination therapy in UK primary care.
methodsUsing the Clinical Practice Research Datalink, we formed a cohort of all patients newly diagnosed with hypertension between 2011 and 2019. We calculated annual proportions of patients newly prescribed first-line monotherapy and combination therapy within 3 months of diagnosis. We used Kaplan-Meier methods to estimate the median treatment persistence, and the probability of persistence at 6 months and 1 year for mono- and combination therapy.
resultsAmong 535 234 patients with hypertension, 1.7% received first-line combination therapy, while 85.6% received monotherapy. Rates of initiation varied by age and hypertension stage. Median treatment persistence was 298 (95% confidence interval [CI] 276-318) days on first-line combination therapy, compared to 398 (95% CI 394-403) days on monotherapy. At 6 months, 58.2% (95% CI 57.2%-59.3%) of combination therapy and 62.2% (95% CI 62.1%-62.4%) of monotherapy initiators remained on first-line treatment; at 1 year the numbers fell to 46.4% (95% CI 45.4%-47.6%) and 51.2% (95% CI 51.1%-51.4%), respectively.
conclusionsFirst-line antihypertensive combination therapy remains exceedingly rare in the UK in accordance with National Institute for Health and Care Excellence guidelines, but in contrast to other international recommendations. Treatment persistence was lower on first-line combination therapy than monotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.